Accounting standard

Boston Beer Reports First Quarter Financial Results

Retrieved on: 
Thursday, April 25, 2024
Advertising, SAM, Hand, Boston Beer Company, Common stock, EPS, Share repurchase, Payment, Growth, Projection, Accounting standard

BOSTON, April 25, 2024 (GLOBE NEWSWIRE) -- The Boston Beer Company, Inc. (NYSE: SAM), today reported financial results for the first quarter ended March 30, 2024.

Key Points: 
  • BOSTON, April 25, 2024 (GLOBE NEWSWIRE) -- The Boston Beer Company, Inc. (NYSE: SAM), today reported financial results for the first quarter ended March 30, 2024.
  • Key results were:
    Repurchased $65.0 million in shares from January 2, 2024 to April 19, 2024
    “We were pleased to see flat depletion trends in the first quarter and to deliver revenue growth,” said Chairman and Founder Jim Koch.
  • “Our first quarter performance reflects a solid start to the year, and we are reiterating our 2024 volume and EPS guidance.
  • The Company’s effective tax rate for the first quarter of 33.0% compared to 27.8% in the prior year.

Golub Capital BDC, Inc. Announces Preliminary Fiscal Year 2024 Second Quarter Financial Results and Declares Fiscal Year 2024 Third Quarter Distribution of $0.39 Per Share

Retrieved on: 
Monday, April 22, 2024
Professional Services, Finance, Prospectus, Investment, Accounting standard, Depreciation, Revenue recognition, Accounting Standards Codification, Form, GCIC, Acquisition, Eastern Time Zone, Consolidated, Quarter, ID, GAAP, Note

The Company estimates that our GAAP debt-to-equity ratio, net4 decreased to 1.17x as of March 31, 2024.

Key Points: 
  • The Company estimates that our GAAP debt-to-equity ratio, net4 decreased to 1.17x as of March 31, 2024.
  • On April 8, 2024, the Company redeemed $500.0 million in aggregate principal amount of its 3.375% Notes due in 2024 (the “2024 Notes”).
  • The 2024 Notes were redeemed at 100% of their principal amount, plus the accrued and unpaid interest thereon.
  • An archived replay of the call will be available shortly after the call until 11:59 p.m. (Eastern Time) on May 21, 2024.

AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results

Retrieved on: 
Friday, March 22, 2024
Research, Separation, Biotechnology, Regeneration, AgeX Therapeutics, Finance, Exchange, Accounting standard, Insurance, Bank statement, ASC, Therapy, Patent, Private law, Consultant, Ageing

ALAMEDA, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for fourth quarter and the full year ended December 31, 2023 and recent highlights.

Key Points: 
  • ALAMEDA, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for fourth quarter and the full year ended December 31, 2023 and recent highlights.
  • The Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of AgeX common stock on February 1, 2024.
  • As of December 31, 2023, AgeX owed Juvenescence Limited $4.5 million in principal and origination fees on account of loans extended to AgeX.
  • Operating expenses for the full year 2023 were $10.1 million as compared with $7.0 million in the same period of 2022.

Golub Capital BDC, Inc. Announces Preliminary Fiscal Year 2024 First Quarter Financial Results and Declares Increased Quarterly Distribution to $0.39 Per Share

Retrieved on: 
Wednesday, January 17, 2024
Asset Management, Professional Services, Finance, GCIC, Accounting standard, Revenue recognition, GAAP, Investment, Acquisition, Depreciation, Consolidated, Quarter, Accounting Standards Codification, ID, Eastern Time Zone, Security (finance)

The Company estimates that the number of non-accrual investments remained at nine investments as of December 31, 2023.

Key Points: 
  • The Company estimates that the number of non-accrual investments remained at nine investments as of December 31, 2023.
  • GBDC’s Board expects to continue to evaluate the potential for supplemental distributions under its quarterly variable supplemental distribution framework, which was introduced in fiscal year 2023.
  • 1 On September 16, 2019, the Company completed its acquisition of Golub Capital Investment Corporation (“GCIC”).
  • The Company will host an earnings conference call at 1:00 pm (Eastern Time) on Tuesday, February 6, 2024 to discuss the quarterly financial results.

AgeX Therapeutics Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 14, 2023
Research, Other Health, Pharmaceutical, Consumer Electronics, Consumer, Technology, Science, Biotechnology, Stem Cells, Seniors, Health, Diabetes, Other Science, Sale, Classification, NYSE, AgeX Therapeutics, Therapy, Preferred stock, Regeneration, Bank statement, Security agreement, Agreement, ASC, Accounting standard, Exchange, GAAP, Private law, Finance, Ageing, Security, Plan, Sino-Japanese Journalist Exchange Agreement, Pharmaceutical industry, Security (finance)

AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter and nine months ended September 30, 2023.

Key Points: 
  • AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter and nine months ended September 30, 2023.
  • On October 31, 2023, AgeX made a final draw of loan funds available under a line of credit from Juvenescence Limited.
  • Cash, cash equivalents, and restricted cash totaled $0.4 million as of September 30, 2023.
  • These factors raise substantial doubt regarding the ability of AgeX to continue as a going concern.

The Simply Good Foods Company Reports Fiscal Fourth Quarter and Full Fiscal Year 2023 Financial Results and Provides Full Fiscal Year 2024 Outlook

Retrieved on: 
Tuesday, October 24, 2023
Adjustment, Derivative, International, Health, The Good Food Institute, Earnings per share, Bellisio Foods, Convenience, EBITDA, G&A, Accounting standard, GAAP, Acquisition, Interest, Debt, Internet, Advertising, Tax, Growth, EPS, Marketing, Depreciation, Overalls, Snack, Investment, IRI, Video game, Music, Pharmaceutical industry, Bookkeeping, Oil, Security (finance), Quest

Fourth quarter fiscal 2023 net sales growth of about 17% was in line with estimates.

Key Points: 
  • Fourth quarter fiscal 2023 net sales growth of about 17% was in line with estimates.
  • In the fourth quarter of fiscal 2023, total Simply Good Foods combined measured and unmeasured channel U.S. retail takeaway increased about 11%.
  • Gross margin was 37.6% in the fourth quarter of fiscal 2023 versus 37.1% last year, an increase of 50 basis points.
  • In the fourth quarter of fiscal 2023, the Company reported net income of $36.6 million compared to $30.1 million for the comparable period of fiscal 2022.

Canadian Sustainability Standards Board continues its momentum welcoming 3 new members; meets with International Sustainability Standards Board

Retrieved on: 
Thursday, September 14, 2023
International Sustainability Standards Board, Public affairs, Senior, Investment, Social engagement, Head, Public Sector Pension Investment Board, BDC, Accounting standard, Joint Monitoring and Implementation Committee, FAQ, Organization, Financial Stability Oversight Council, Climate change, Sustainability, Diversity, Business Development Bank of Canada, Knowledge, Assurance, Disclosure, PSP, ISSB, Audit, Industrial design, Management, Medical device

TORONTO, Sept. 14, 2023 /CNW/ - The Canadian Sustainability Standards Board (CSSB) continues its momentum to support the uptake of international sustainability standards in Canada, appointing three new members to expand its geographical representation and breadth of expertise, while continuing to foster its relationship with the International Sustainability Standards Board (ISSB).

Key Points: 
  • TORONTO, Sept. 14, 2023 /CNW/ - The Canadian Sustainability Standards Board (CSSB) continues its momentum to support the uptake of international sustainability standards in Canada, appointing three new members to expand its geographical representation and breadth of expertise, while continuing to foster its relationship with the International Sustainability Standards Board (ISSB).
  • "We are excited to welcome three additional, proven leaders in sustainability to our board.
  • "We are focused on ensuring meaningful engagement with those who are impacted and affected by the first international sustainability standards."
  • Collaboration with Canada's regulatory bodies, which determine the mandatory application rules of standards for Canada's publicly accountable enterprises, will continue.

IF Bancorp, Inc. Announces Results for Fourth Quarter and Fiscal Year Ended June 30, 2023

Retrieved on: 
Thursday, August 31, 2023
Banking, Accounting, Professional Services, Finance, Borrowing base, COVID-19, PSLRA, Clifton Bancorp, Inc., Accounting standard, ESOP, Sale, Depreciation, ASU, Security (finance), Annual report, Hudson City Bancorp, Cryptocurrency, Bank

Interest income increased to $32.1 million for the year ended June 30, 2023, from $24.8 million for the year ended June 30, 2022.

Key Points: 
  • Interest income increased to $32.1 million for the year ended June 30, 2023, from $24.8 million for the year ended June 30, 2022.
  • Interest expense increased to $10.1 million for the year ended June 30, 2023, from $2.5 million for the year ended June 30, 2022.
  • Non-interest income decreased to $4.1 million for the year ended June 30, 2023, from $5.5 million for the year ended June 30, 2022.
  • Non-interest expense increased to $20.0 million for the year ended June 30, 2023, from $19.4 million for the year ended June 30, 2022.

Pacific Coast Oil Trust Announces There Will Be No August Cash Distribution

Retrieved on: 
Wednesday, August 23, 2023
Oil, Gas, Energy, Superior court, Accounting standard, Internet, Motion, Retirement, Court, Accounting Standards Codification, Transport, Phillips 66, Prejudice, Form 8-K, Face, Conveyance, Moss Adams, ARO, Consultant, Panel, Hearing, Security (finance), Trustee, California superior courts, County, Net, Evergreen, Interest, Business analyst, COVID-19, Phillips, Annual report, Connection, Probability, Bank statement, Calendar, Sale, Report, Martindale, Cryptocurrency, Life insurance, Trust

ARO is the recognition related to net present value of future plugging and abandonment costs that all oil and gas operators face.

Key Points: 
  • ARO is the recognition related to net present value of future plugging and abandonment costs that all oil and gas operators face.
  • As a result, the total proceeds received by the Trust in each of 2020 and 2021 were less than $2.0 million.
  • Pacific Coast Oil Trust is a Delaware statutory trust formed by PCEC to own interests in certain oil and gas properties in the Santa Maria Basin and the Los Angeles Basin in California (the “Underlying Properties”).
  • Any anticipated distribution is based, in part, on the amount of cash received or expected to be received by the Trust from PCEC with respect to the relevant period.

AgeX Therapeutics Reports Second Quarter 2023 Financial Results

Retrieved on: 
Monday, August 14, 2023
Research, Seniors, Diabetes, Stem Cells, Biotechnology, Health, Consumer, Pharmaceutical, Science, External commercial borrowing, AgeX Therapeutics, Sino-Japanese Journalist Exchange Agreement, ASC, Interim, Tuck School of Business, Therapy, Private law, Bank statement, Audit committee, Ageing, Business, Accounting standard, Exchange, MBA, Finance, Separation, Regeneration, The Sovereign Fund of Egypt, Dartmouth University, Employment, Pre-consultation Agreement (Japan), NYSE, Compensated emancipation, Edmonton Transit Service, Pharmaceutical industry, Cryptocurrency, Security (finance), Management, MD

AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter and six months ended June 30, 2023.

Key Points: 
  • AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter and six months ended June 30, 2023.
  • Cash, cash equivalents, and restricted cash totaled $0.3 million as of June 30, 2023.
  • As of June 30, 2023, AgeX owed Juvenescence Limited (“Juvenescence”) $33 million in principal and origination fees on account of loans extended to AgeX.
  • Operating expenses: Operating expenses for the three months ended June 30, 2023 were $1.9 million, as compared with $1.6 million for the same period in 2022.